AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02717390 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Texts for Child Safety (TCS)
Description: The purpose of the injury prevention arm is to reduce the prevalence of safety hazards in the home and car environments, decrease the number of self-reported and medically-attended injuries among children, and increase caregiver's self-reported safety behaviors and knowledge of child safety. The Investigators will compare the results of our tailored child safety intervention (Texts for Child Safety \[TCS\]) among participants in the injury prevention arm with those randomized to the BB3 arm.
Study NCT04407962 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS group
Description: The experimental treatment will consist of health promoting text messages addressing metabolic risk factors associated with cardiovascular disorders in patients with hypertension. The text messages will be developed to support healthy life style changes i.e. regarding general cardiovascular health, tobacco use, physical activity and diet.
Study NCT02804945 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells (MSCs)
Description: Participants receive a maximum dose of 3 x 10\^6 cell/Kg by vein one time on Day 1.
Study NCT01604694 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: TAP Block
Description: An Ultra Sound-guided TAP block is performed after induction of general anesthesia prior to surgical incision. The syringes containing either saline 20 ml (placebo group) or levobupivacaine 20 ml are prepared by the hospital pharmacy under aseptic conditions.
Study NCT01604694 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP Block
Description: An Ultra Sound-guided TAP block is performed after induction of general anesthesia prior to surgical incision. The syringes containing either saline 20 ml (placebo group) or levobupivacaine 20 ml are prepared by the hospital pharmacy under aseptic conditions.
Study NCT01248247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg by mouth each day of a 28 day cycle.
Study NCT01248247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: 100 mg by mouth daily of a 28 day cycle.
Study NCT01248247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: 100 mg by mouth every week of a 28 day cycle.
Study NCT01248247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400 mg by mouth twice a day for a 28 day cycle.
Study NCT01248247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg by mouth daily of a 28 day cycle.
Study NCT01248247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: 135 mg by mouth every week of a 28 day cycle.
Study NCT01940094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg Prednisone
Description: Subjects will remain on daily prednisone dose of 5 mg
Study NCT00455117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Parecoxib ('Dynastat' Pfizer)
Description: parecoxib or placebo
Study NCT00455117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Parecoxib ('Dynastat' Pfizer)
Description: parecoxib or placebo
Study NCT01940094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0 mg Prednisone
Description: Subjects will taper their prednisone dose from 5 mg per day to 0 mg per day
Study NCT03033576 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Given IV
Study NCT03033576 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT03033576 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT01269593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET Imaging using 124 IPUH71
Description: A dose of up to 11.0 mCi (range: 4.0-11.0 mCi) of 124I-PUH71 will be administered intravenously with the patient at rest. 124I-PUH71 scans will be performed at immediately and/or 3-4 hours, 20-24 hours, and 40-80 hours after injection of the radiotracer. Optionally, in willing patients scans will be performed 160-200 hours (\~7-8 days) after injection of the radiotracer. At each time-point, a 45-60 minute axial body image is acquired. Images will be acquired on a state-of-the-art PET-CT scanner. A low-dose CT will be obtained immediately-prior to PET imaging, at each time-point. A 30-45 minute scanning timeperiod is typical for clinical PET studies.
Study NCT03375320 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection
Study NCT03375320 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection
Study NCT03375320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO
Study NCT03375320 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT03375320 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT
Study NCT03375320 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03375320 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03375320 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT03375320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03375320 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03375320 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-ray
Study NCT03375320 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: X-Ray Imaging
Description: Undergo x-ray
Study NCT03069924 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gain-framed messaging
Description: Gain-framed messaging materials
Study NCT03069924 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Unframed messaging materials
Description: Unframed smoking cessation materials
Study NCT03232008 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Canderel drink
Description: 1.4% aspartame and 0.95% acesulfame-k and 95% maltodextrin; 3g dissolved in 250ml of water
Study NCT03232008 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Canderel+Lyle's Golden Syrup drink
Description: Canderel: 1.4% aspartame and 0.95% acesulfame-k and 95% maltodextrin; 3g dissolved in 250ml of water Lyle's Golden Syrup: 35 g (27g of glucose and fructose)
Study NCT05110209 — intervention group
Intervention type: OTHER
Intervention: Aflibercept
Description: intravitreal injection
Study NCT05110209 — intervention group
Intervention type: OTHER
Intervention: Ranibizumab
Description: intravitreal injection
Study NCT05110209 — intervention group
Intervention type: OTHER
Intervention: Bevacizumab
Description: intravitreal injection
Study NCT02935686 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.Mos4.HIV
Description: Ad26.Mos4.HIV at a dose of 5\*10\^10 viral particles (vp), administered intramuscularly.
Study NCT02935686 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clade C gp140 plus adjuvant
Description: Clade C gp140 vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 milliliter (mL) injection administered intramuscularly.
Study NCT02935686 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clade C gp140/Mosaic gp140 plus adjuvant
Description: Clade C gp140 and Mosaic gp140 (each 125 mcg of total protein) mixed with aluminum phosphate adjuvant, per 0.5 milliliter (mL) injection, administered intramuscularly.
Study NCT02935686 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Containing 0.9 percent normal saline, administered intramuscularly.
Study NCT02935686 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp140 HIV Bivalent Vaccine
Description: gp140 HIV Bivalent Vaccine is adjuvanted protein co-formulation with a dosage strength of 80 mcg Clade C protein, 75 mcg Mosaic protein and 425 mcg aluminum (as aluminum phosphate adjuvant).
Study NCT01946204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: 240 mg tablets administered by mouth on a continuous once daily dosing regimen
Study NCT01946204 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo tablets administered by mouth on a continuous once daily dosing regimen
Study NCT03038048 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Varying needle size with intravitreal ranibizumab or aflibercept
Description: Varying gauge of needle, 33 gauge vs 30 gauge
Study NCT04165564 — intervention group
Intervention type: OTHER
Intervention: Institutional standard of care
Description: Institutional standard of care may involve the use of LungRADS (screening setting) or Fleischner criteria (either combined 2005, 2013 or 2017 guidelines)
Study NCT00891995 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed loop
Description: Closed loop therapy for up to 4 to 6 days
Study NCT00891995 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home glucose monitoring
Description: Standard diabetes management using a home glucose meter.
Study NCT00891995 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home glucose monitoring
Description: Standard diabetes management using a home glucose meter.
Study NCT00891995 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin pump
Description: Insulin pump use for 2 years
Study NCT00891995 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitor
Description: Continuous glucose monitor use for 2 years
Study NCT02859155 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Multivisceral en bloc resection surgery
Description: Multivisceral en bloc resection for colorectal cancer in advance patients (T4)
Study NCT03472508 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Folic Acid
Description: Folic acid used in this study are listed products. All drugs used in the double-blind treatment period of this study will be loaded into safety capsules with the same outer appearance; all parties involved in the trial will be unaware of the contents of the capsules.
Study NCT03472508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Folic acid used in this study are listed products. All drugs used in the double-blind treatment period of this study will be loaded into safety capsules with the same outer appearance; all parties involved in the trial will be unaware of the contents of the capsules.
Study NCT04165564 — intervention group
Intervention type: OTHER
Intervention: Biosamples of airway and blood
Description: Identify biomarkers in biosamples from airway and blood for the preclinical detection of lung cancer.
Study NCT02330068 — intervention group
Intervention type: DRUG
Intervention: citalopram
Description: Cases
Study NCT02209480 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alexander Technique
Study NCT02209480 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heat pad application
Study NCT02209480 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: guided imagery
Study NCT00153803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib (tarceva)
Description: Erlotinib 150mg orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events, death or completion of 3 years of therapy.
Study NCT00153803 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events death or completion of 3 years of therapy.
Study NCT01743326 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radio Frequency Denervation
Study NCT01743326 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local Anesthesia
Study NCT01743326 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local Anesthesia
Study NCT03726788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A 100U
Description: one intra-articular injection of 100 U of botulinum toxin type A, diluted in 2 ml of 0.9% SSI
Study NCT03726788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A 200U
Description: one intra-articular injection of 200 U of botulinum toxin type A, diluted in 4 ml of 0.9% SSI
Study NCT03726788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Hexacetonide Inj Susp 20 MG/ML
Description: one intra-articular injection of 2 ml Triamcinolone Hexacetonide
Study NCT03222765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo, metformin, linagliptin, linagliptin + metformin
Study NCT03222765 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, metformin, linagliptin, linagliptin + metformin
Study NCT03079128 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Weight Watchers Intervention
Study NCT00216463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 301012 or Placebo
Description: 200 mg subcutaneous injection - 4 loading doses within the first 11 days followed by: 200 mg subcutaneous injection - every other week for 11 weeks
Study NCT00216463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 301012 or Placebo
Description: 200 mg subcutaneous injection - 4 loading doses within the first 11 days followed by: 100 mg subcutaneous injection - every other week for 11 weeks
Study NCT00216463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 301012 or Placebo
Description: 300 mg subcutaneous injection - every week for 13 weeks
Study NCT00216463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 301012 or Placebo
Description: 400 mg subcutaneous injection - every week for 13 weeks
Study NCT00216463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 301012 or Placebo
Description: 200 mg subcutaneous injection - every week for 13 weeks
Study NCT03436225 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone orally.
Description: Administered orally (0.15mg /kg / dose) twice daily for 3 to 5 days.
Study NCT03436225 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone parenteral.
Description: Administered parenteral (0.15mg /kg / dose) twice daily for 3 to 5 days.
Study NCT03436225 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled nebulized Budesonide.
Description: Administered for inhalation (1 mg/ 2ml) twice daily for 3 to 5 days.
Study NCT03436225 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled nebulized salbutamol.
Description: Administered for inhalation (0.15mg /kg / dose) daily every 6-8hrs
Study NCT00011570 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Bladder & Bowel Control
Study NCT03056937 — intervention group
Intervention type: OTHER
Intervention: Bariatric surgery
Description: evaluations pre and post bariatric surgery.
Study NCT03056937 — intervention group
Intervention type: OTHER
Intervention: Control
Description: without intervention, it will be performed only evaluations
Study NCT00059865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT00059865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Study NCT03453125 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Spanish modified Story Memory Technique (mSMT)
Study NCT03453125 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spanish modified Story Memory Technique (mSMT)
Study NCT04423263 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral internal iliac artery balloon occlusion
Description: Bilateral internal iliac artery balloon placement under fluoroscopic guidance preoperatively which will be occluded intraoperatively based on existing local protocol
Study NCT04423263 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Surgical approach similar to intervention arm, except bilateral internal iliac artery occlusion
Study NCT00699491 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cixutumumab
Description: Given IV
Study NCT00699491 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00699491 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00699491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV
Study NCT03701256 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral ultrasound guided TAP bloc
Description: In the TAP group: Bilateral ultrasound guided TAP bloc for laparoscopic gynecologic surgery
Study NCT03701256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular blockade agent: Atracurium 01mg/kg per bolus
Description: In the TRAC group: Neuromuscular blockade agent: Atracurium 01mg/kg per bolus for maintaining muscular relaxation and immobilization during laparoscopic gynecologic surgery
Study NCT00254644 — intervention group
Intervention type: PROCEDURE
Intervention: Morphological and functional MRI
Description: one time
Study NCT02389491 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: normal density formula (Necocate)
Description: In control group,there are 32 infants
Study NCT02389491 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high density formula(Infatrini)
Description: In intervention group,there are 32 infants
Study NCT03571893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Watchers Freestyle (Flex)
Description: Participants will be referred to their local Weight Watchers meeting and provided with a promotional code to allow them to participate in the Weight Watchers program free of charge for 12 months. At the randomization visit, study staff will help participants identify a convenient Weight Watchers meeting location and download the program app onto their smartphone.
Study NCT03571893 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DIY Personal Plan
Description: Participants will be provided with a written resource with descriptions of a variety of approaches that have been shown to promote healthy weight loss through behavioral modification. Participants will be encouraged to assess their preferences for dietary change and physical activity and adopt an approach that will lead to negative energy balance and moderate (1-2 lbs. per week) weight loss.
Study NCT05035355 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: a weaning protocol
Description: a weaning protocol that is combined spontaneous breathing trial (SBT) with the high-flow nasal cannula (HFNC)
Study NCT03343730 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Non-mydriatic color fundus photography with the RetinaVue camera
Description: This hand-held device allows the primary care physician to capture an image of the patient's retina and transmit the image to a board-certified ophthalmologist for interpretation.
Study NCT03343730 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Referral for dilated eye exam with an eye care professional
Description: All patients will be given a referral to an eye care professional for a routine, dilated, diabetic eye exam.
Study NCT00533663 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Healing Touch
Description: every other week (during their infusion)
Study NCT00533663 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Adriamycin, cyclophosphamide, and paclitaxel administered as standard of care
Study NCT00533663 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Adriamycin, cyclophosphamide, and paclitaxel administered as standard of care
Study NCT00533663 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: guided relaxation
Study NCT04506502 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The ZELTIQ System
Description: The MMS device will be used to perform the treatments.
Study NCT03423849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: 25mg/m2,day 1 and day 8, every 3 weeks
Study NCT03423849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1250mg/m2,day 1 and day 8, every 3 weeks
Study NCT03423849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25mg/m2,day 1,every 3 weeks